Fixation stability and implication for multifocal electroretinography in patients with neovascular age-related macular degeneration after anti-VEGF treatment
- PMID: 27080862
- DOI: 10.1007/s00417-016-3323-0
Fixation stability and implication for multifocal electroretinography in patients with neovascular age-related macular degeneration after anti-VEGF treatment
Abstract
Purpose: To quantify fixation stability in patients with neovascular age-related macular degeneration (nAMD) at baseline, 3 and 6 months after anti-vascular endothelial growth factor (anti-VEGF) treatment and furthermore asses the implications of an unsteady fixation for multifocal electroretinography (mfERG) measurements.
Methods: Fifty eyes of 50 nAMD patients receiving intravitreal anti-VEGF treatment with either bevacizumab or ranibizumab and eight eyes of eight control subjects were included. Fixation stability measurements were performed with the Eye-Link eyetracking system and the retinal area in degrees2 (deg2) containing the 68 % most frequently used fixation points (RAF68) was calculated. MfERG P1 amplitude and implicit time were analyzed in six concentric rings and as a summed response. Patients were examined at baseline, 3 and 6 months. Four different mfERG recordings were performed for the control subjects to mimic an involuntary unstable fixation: normal central fixation, 2.4°, 4.8°, and 7.1° fixation instability.
Results: For control subjects, a fixation instability of 2.4° (corresponding to the central hexagon) did not reduce mfERG ring amplitudes significantly, whereas 4.8° and 7.1° fixation instability reduced the amplitudes significantly in rings 1 and 2 (p < 0.001) as well as in the peripheral rings in the 7.1° instability condition (p < 0.001). Fixation stability improved non-significantly for patients at 3 and 6 months. The size of the retinal area of fixation was at baseline, 3 and 6 months negatively correlated to visual acuity (VA) (rbaseline = -0.65, r3 months = -0.60, and r6 months = -0.66 respectively, p < 0.001) and mfERG amplitudes of the three innermost rings (rbaseline = -0.29, p = 0.042, r3 months = -0.43, p = 0.003 and r6 months = -0.31, p = 0.042). The VA cutoff for a fixation area less than 5 deg2 (approximately the central hexagon) was 65, 77, and 68 ETDRS letters (corresponding a maximal Snellen equivalent of 0.31) at baseline, 3 and 6 months, respectively.
Conclusions: MfERG amplitudes in recordings of nAMD patients are at substantial risk of being reduced due to poor fixation as a large number of patients may use a fixation area of more than 5 deg2. Fixation monitoring during recording as well as interpretation of results should be performed with care, especially in patients with poor visual acuity.
Keywords: Age-related macular degeneration; Anti-VEGF; Electrophysiology; Fixation stability; Multifocal ERG; Retinal area of fixation (RAF68).
Similar articles
-
Early multifocal electroretinogram findings during intravitreal ranibizumab treatment for neovascular age-related macular degeneration.Invest Ophthalmol Vis Sci. 2011 Jun 1;52(6):3446-51. doi: 10.1167/iovs.10-6588. Invest Ophthalmol Vis Sci. 2011. PMID: 21357390
-
NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators.Retina. 2017 Feb;37(2):257-264. doi: 10.1097/IAE.0000000000001150. Retina. 2017. PMID: 27429385
-
Fixation stability measurements in patients with neovascular age-related macular degeneration treated with ranibizumab.Can J Ophthalmol. 2013 Oct;48(5):394-9. doi: 10.1016/j.jcjo.2013.04.006. Can J Ophthalmol. 2013. PMID: 24093186
-
Defining response to anti-VEGF therapies in neovascular AMD.Eye (Lond). 2015 Jun;29(6):721-31. doi: 10.1038/eye.2015.48. Epub 2015 Apr 17. Eye (Lond). 2015. PMID: 25882328 Free PMC article. Review.
-
Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems.BMC Ophthalmol. 2020 Jul 17;20(1):294. doi: 10.1186/s12886-020-01554-2. BMC Ophthalmol. 2020. PMID: 32680477 Free PMC article.
Cited by
-
Reply to the letter to the editor: Multifocal electroretinography in amblyopia.Graefes Arch Clin Exp Ophthalmol. 2020 May;258(5):1139-1140. doi: 10.1007/s00417-020-04657-0. Epub 2020 Mar 28. Graefes Arch Clin Exp Ophthalmol. 2020. PMID: 32222829 No abstract available.
-
Electrophysiological evaluation and 18-month follow-up of two regimens with aflibercept for neovascular age-related macular degeneration.Doc Ophthalmol. 2022 Apr;144(2):99-115. doi: 10.1007/s10633-021-09863-7. Epub 2022 Feb 26. Doc Ophthalmol. 2022. PMID: 35218455 Free PMC article. Clinical Trial.
-
Additional measures of macular function beyond visual acuity.Graefes Arch Clin Exp Ophthalmol. 2024 Jun;262(6):1723-1736. doi: 10.1007/s00417-023-06272-1. Epub 2023 Nov 8. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 37938378 Free PMC article. Review.
-
Correlation of macular sensitivity measures and visual acuity to vision-related quality of life in patients with age-related macular degeneration.BMC Ophthalmol. 2021 Mar 23;21(1):149. doi: 10.1186/s12886-021-01901-x. BMC Ophthalmol. 2021. PMID: 33757447 Free PMC article.
-
Effect of eccentric fixation on the steady-state pattern electroretinogram.Doc Ophthalmol. 2024 Apr;148(2):87-95. doi: 10.1007/s10633-024-09967-w. Epub 2024 Feb 28. Doc Ophthalmol. 2024. PMID: 38416305 Free PMC article.
References
-
- Graefes Arch Clin Exp Ophthalmol. 2002 Sep;240(9):765-70 - PubMed
-
- J Neuroophthalmol. 2003 Sep;23(3):225-35 - PubMed
-
- Semin Ophthalmol. 2004 Mar-Jun;19(1-2):55-61 - PubMed
-
- Graefes Arch Clin Exp Ophthalmol. 2005 Sep;243(9):903-10 - PubMed
-
- Graefes Arch Clin Exp Ophthalmol. 2006 Oct;244(10):1273-82 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources